Related Experiment Video
Updated: Mar 16, 2026
12:33
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
48.7K
[Not Available].
Denis Moro-Sibilot1, Léonie Ferrer2, Matteo Giaj Levra2
1UM Oncologie Thoracique, Clinique de pneumologie, PTV CHU Grenoble-Alpes, CS10217 38043 Grenoble cedex; Inserm U823, Institut Albert Bonniot, Rond-point de la chantourne 38700 La tronche.
Bulletin Du Cancer
|August 7, 2016
Summary
Nivolumab shows promise in lung cancer treatment, offering an alternative to docetaxel with a better safety profile. This immunotherapy is changing clinical practice and future treatment strategies.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Docetaxel has been a standard second-line treatment for lung cancer for over 15 years.
- Docetaxel is associated with a significant and unfavorable safety profile.
- There is a need for improved treatment options in the second-line setting for lung cancer.
Purpose of the Study:
- To explore recent findings on nivolumab in the second-line treatment of lung cancer.
- To discuss the impact of nivolumab on current clinical practice.
- To consider future directions for nivolumab and other immune oncology drugs in lung cancer care.
Main Methods:
- Review of results from two randomized phase III trials (Check-Mate-017 and Check-Mate-057).
- Analysis of nivolumab's efficacy and safety in the second-line lung cancer setting.
- Discussion of clinical implications and future research avenues.
Main Results:
- Nivolumab has demonstrated significant clinical benefit in previously treated non-small cell lung cancer (NSCLC).
- Check-Mate-017 and Check-Mate-057 trials established nivolumab as a viable alternative to chemotherapy.
- Nivolumab offers an improved safety profile compared to traditional chemotherapy agents like docetaxel.
Conclusions:
- Nivolumab represents a paradigm shift in the second-line treatment of lung cancer.
- The success of nivolumab supports the broader application of immune oncology drugs.
- Further research is warranted to optimize the use of nivolumab and explore novel immunotherapy combinations.
